Prime Medicine (PRME) Competitors

Prime Medicine logo
$4.19 -0.08 (-1.87%)
Closing price 04:00 PM Eastern
Extended Trading
$4.20 +0.00 (+0.12%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRME vs. BEAM, CRSP, VKTX, CELC, and DYN

Should you buy Prime Medicine stock or one of its competitors? Prime Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Viking Therapeutics (VKTX), Celcuity (CELC), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 24 mentions for Beam Therapeutics and 23 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.73 beat Prime Medicine's score of 0.58 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics currently has a consensus price target of $47.64, suggesting a potential upside of 108.35%. Prime Medicine has a consensus price target of $7.86, suggesting a potential upside of 84.01%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A

Beam Therapeutics has a net margin of -73.04% compared to Prime Medicine's net margin of -2,497.56%. Beam Therapeutics' return on equity of -32.76% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
Prime Medicine -2,497.56%-222.88%-59.68%

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market.

Summary

Beam Therapeutics beats Prime Medicine on 12 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to CRISPR Therapeutics?

Prime Medicine (NASDAQ:PRME) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Prime Medicine had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 23 mentions for Prime Medicine and 17 mentions for CRISPR Therapeutics. Prime Medicine's average media sentiment score of 0.58 beat CRISPR Therapeutics' score of 0.15 indicating that Prime Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
CRISPR Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Prime Medicine currently has a consensus target price of $7.86, suggesting a potential upside of 84.01%. CRISPR Therapeutics has a consensus target price of $72.93, suggesting a potential upside of 72.65%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

Prime Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A
CRISPR Therapeutics$3.51M1,167.32-$581.60M-$4.74N/A

CRISPR Therapeutics has a net margin of -1,812.07% compared to Prime Medicine's net margin of -2,497.56%. CRISPR Therapeutics' return on equity of -25.59% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-2,497.56% -222.88% -59.68%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

Prime Medicine has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Summary

Prime Medicine beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Viking Therapeutics currently has a consensus price target of $93.36, indicating a potential upside of 219.52%. Prime Medicine has a consensus price target of $7.86, indicating a potential upside of 84.01%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Viking Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market.

Prime Medicine has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$5.40N/A
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A

Viking Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -2,497.56%. Viking Therapeutics' return on equity of -117.35% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -117.35% -88.87%
Prime Medicine -2,497.56%-222.88%-59.68%

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Prime Medicine had 7 more articles in the media than Viking Therapeutics. MarketBeat recorded 23 mentions for Prime Medicine and 16 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.83 beat Prime Medicine's score of 0.58 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
9 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Prime Medicine beats Viking Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to Celcuity?

Prime Medicine (NASDAQ:PRME) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Prime Medicine had 11 more articles in the media than Celcuity. MarketBeat recorded 23 mentions for Prime Medicine and 12 mentions for Celcuity. Prime Medicine's average media sentiment score of 0.58 beat Celcuity's score of 0.51 indicating that Prime Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Celcuity
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Prime Medicine has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Celcuity has lower revenue, but higher earnings than Prime Medicine. Celcuity is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A
CelcuityN/AN/A-$177.04M-$4.71N/A

Prime Medicine currently has a consensus target price of $7.86, suggesting a potential upside of 84.01%. Celcuity has a consensus target price of $151.79, suggesting a potential upside of 135.80%. Given Celcuity's higher possible upside, analysts clearly believe Celcuity is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Celcuity
2 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.69

Celcuity has a net margin of 0.00% compared to Prime Medicine's net margin of -2,497.56%. Prime Medicine's return on equity of -222.88% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-2,497.56% -222.88% -59.68%
Celcuity N/A -1,522.54%-42.11%

Summary

Prime Medicine beats Celcuity on 10 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Dyne Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -2,497.56%. Dyne Therapeutics' return on equity of -69.73% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
Prime Medicine -2,497.56%-222.88%-59.68%

Dyne Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market.

Prime Medicine has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dyne Therapeutics currently has a consensus price target of $31.29, suggesting a potential upside of 82.32%. Prime Medicine has a consensus price target of $7.86, suggesting a potential upside of 84.01%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

In the previous week, Prime Medicine had 10 more articles in the media than Dyne Therapeutics. MarketBeat recorded 23 mentions for Prime Medicine and 13 mentions for Dyne Therapeutics. Prime Medicine's average media sentiment score of 0.58 beat Dyne Therapeutics' score of 0.18 indicating that Prime Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Prime Medicine beats Dyne Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRME vs. The Competition

MetricPrime MedicineBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$759.97M$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-4.3624.2434.3430.11
Price / Sales186.5914.858.005.32
Price / CashN/A21.8921.0222.34
Price / Book6.254.354.763.85
Net Income-$201.14M-$24.19M$3.52B$393.14M
7 Day Performance-2.56%-7.26%-5.34%-4.53%
1 Month Performance20.75%-4.96%-3.61%-5.86%
1 Year Performance24.33%-2.87%0.01%-7.78%

Prime Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRME
Prime Medicine
3.4893 of 5 stars
$4.19
-1.9%
$7.86
+87.5%
+26.7%$759.97M$4.07MN/A146
BEAM
Beam Therapeutics
2.743 of 5 stars
$27.46
+4.3%
$46.90
+70.8%
+5.3%$2.82B$139.74MN/A540
CRSP
CRISPR Therapeutics
2.8475 of 5 stars
$51.82
+3.7%
$66.00
+27.4%
-19.6%$4.98B$3.51MN/A393
VKTX
Viking Therapeutics
3.5535 of 5 stars
$27.25
+4.4%
$93.36
+242.7%
-25.3%$3.47BN/AN/A65
CELC
Celcuity
2.7237 of 5 stars
$70.52
+1.1%
$152.57
+116.3%
-30.5%$3.47BN/AN/A155

Related Companies and Tools


This page (NASDAQ:PRME) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners